-
Something wrong with this record ?
Antimicrobial peptide isolated from Bacillus amyloliquefaciens K14 revitalizes its use in combinatorial drug therapy
S. Regmi, YH. Choi, YS. Choi, MR. Kim, JC. Yoo,
Language English Country United States
Document type Journal Article
- MeSH
- Ampicillin pharmacology MeSH
- Anti-Bacterial Agents biosynthesis isolation & purification pharmacology MeSH
- Bacillus amyloliquefaciens classification immunology metabolism MeSH
- Biofilms drug effects growth & development MeSH
- Chromatography, Ion Exchange MeSH
- Vancomycin-Resistant Enterococci drug effects growth & development MeSH
- Phylogeny MeSH
- Antimicrobial Cationic Peptides biosynthesis isolation & purification pharmacology MeSH
- Drug Therapy, Combination MeSH
- Microbial Sensitivity Tests MeSH
- Oxacillin pharmacology MeSH
- Vancomycin Resistance drug effects MeSH
- Amino Acid Sequence MeSH
- Protein Stability MeSH
- Staphylococcus aureus drug effects growth & development MeSH
- Drug Synergism MeSH
- Publication type
- Journal Article MeSH
The present study was performed to evaluate the antibacterial activities of an antimicrobial peptide (CSpK14) and the synergies thereof with β-lactams against vancomycin-resistant Staphylococcus aureus (VRSA) and Enterococci (VRE). Our strain was isolated from fermented food (kimchi), which is 99.79 % homologous with Bacillus amyloliquefaciens subsp. plantarum FZB42(T). CSpK14 was purified to homogeneity by diammonium sulfate precipitation, concentration, dialysis, and followed by two-stage chromatographic separation, i.e., Sepharose Cl-6B and Sephadex G-25 chromatography, and had a molar mass of ~4.6 kDa via Tricine SDS-PAGE and in situ examination. It was stable at pH 6.0-11.5 and temperature up to 80 °C. In addition, it was also stable with various metal ions, solvents, and proteases. The N-terminal amino acid sequence was H-Y-D-P-G-D-D-S-G-N-T-G and did not show any significant homology with reported peptides. However, it shows some degrees of identity with alpha-2-macroglobulin and ligand-gated channel protein from different microorganisms. CSpK14 significantly reduced the minimum inhibitory concentrations (MICs) of β-lactams and had no effect on non-β-lactams against VRSA and VRE. MICs of CSpK14/oxacillin and CSpK14/ampicillin were reduced by 8- to 64-fold and 2- to 16-fold, respectively. The time killing assay between CSpK14/oxacillin (2.29-2.37 Δlog10CFU/mL at 24 h) and CSpK14/ampicillin (2.30-2.38 Δlog10CFU/mL at 24 h) being >2-fold and fractional inhibitory concentration index ˂0.5 revealed synergy. Furthermore, the biofilms formed by VRSA and VRE were reduced completely. CSpK14 was simple to purify, had low molecular mass, was stable over a wide pH range or tested chemicals, had broad inhibitory spectrum, and possessed potent synergistic antimicrobial-antibiofilm properties. CSpK14 synergistically enhanced the efficacy of β-lactams and is therefore suitable for combination therapy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17010574
- 003
- CZ-PrNML
- 005
- 20170321103330.0
- 007
- ta
- 008
- 170321s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-016-0479-2 $2 doi
- 035 __
- $a (PubMed)27787755
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Regmi, Sudip $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
- 245 10
- $a Antimicrobial peptide isolated from Bacillus amyloliquefaciens K14 revitalizes its use in combinatorial drug therapy / $c S. Regmi, YH. Choi, YS. Choi, MR. Kim, JC. Yoo,
- 520 9_
- $a The present study was performed to evaluate the antibacterial activities of an antimicrobial peptide (CSpK14) and the synergies thereof with β-lactams against vancomycin-resistant Staphylococcus aureus (VRSA) and Enterococci (VRE). Our strain was isolated from fermented food (kimchi), which is 99.79 % homologous with Bacillus amyloliquefaciens subsp. plantarum FZB42(T). CSpK14 was purified to homogeneity by diammonium sulfate precipitation, concentration, dialysis, and followed by two-stage chromatographic separation, i.e., Sepharose Cl-6B and Sephadex G-25 chromatography, and had a molar mass of ~4.6 kDa via Tricine SDS-PAGE and in situ examination. It was stable at pH 6.0-11.5 and temperature up to 80 °C. In addition, it was also stable with various metal ions, solvents, and proteases. The N-terminal amino acid sequence was H-Y-D-P-G-D-D-S-G-N-T-G and did not show any significant homology with reported peptides. However, it shows some degrees of identity with alpha-2-macroglobulin and ligand-gated channel protein from different microorganisms. CSpK14 significantly reduced the minimum inhibitory concentrations (MICs) of β-lactams and had no effect on non-β-lactams against VRSA and VRE. MICs of CSpK14/oxacillin and CSpK14/ampicillin were reduced by 8- to 64-fold and 2- to 16-fold, respectively. The time killing assay between CSpK14/oxacillin (2.29-2.37 Δlog10CFU/mL at 24 h) and CSpK14/ampicillin (2.30-2.38 Δlog10CFU/mL at 24 h) being >2-fold and fractional inhibitory concentration index ˂0.5 revealed synergy. Furthermore, the biofilms formed by VRSA and VRE were reduced completely. CSpK14 was simple to purify, had low molecular mass, was stable over a wide pH range or tested chemicals, had broad inhibitory spectrum, and possessed potent synergistic antimicrobial-antibiofilm properties. CSpK14 synergistically enhanced the efficacy of β-lactams and is therefore suitable for combination therapy.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a ampicilin $x farmakologie $7 D000667
- 650 _2
- $a antibakteriální látky $x biosyntéza $x izolace a purifikace $x farmakologie $7 D000900
- 650 _2
- $a kationické antimikrobiální peptidy $x biosyntéza $x izolace a purifikace $x farmakologie $7 D023181
- 650 _2
- $a Bacillus amyloliquefaciens $x klasifikace $x imunologie $x metabolismus $7 D000069977
- 650 _2
- $a biofilmy $x účinky léků $x růst a vývoj $7 D018441
- 650 _2
- $a chromatografie iontoměničová $7 D002852
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a oxacilin $x farmakologie $7 D010068
- 650 _2
- $a fylogeneze $7 D010802
- 650 _2
- $a stabilita proteinů $7 D055550
- 650 _2
- $a Staphylococcus aureus $x účinky léků $x růst a vývoj $7 D013211
- 650 _2
- $a rezistence na vankomycin $x účinky léků $7 D020713
- 650 _2
- $a enterokoky rezistentní vůči vankomycinu $x účinky léků $x růst a vývoj $7 D065507
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Choi, Yun Hee $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
- 700 1_
- $a Choi, Yoon Seok $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
- 700 1_
- $a Kim, Mi Ri $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea.
- 700 1_
- $a Yoo, Jin Cheol $u Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, South Korea. jcyu@chosun.ac.kr.
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 62, č. 2 (2017), s. 127-138
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27787755 $y Pubmed
- 910 __
- $a ABA008 $b online $c sign $y a $z 0
- 990 __
- $a 20170321 $b ABA008
- 991 __
- $a 20170321103601 $b ABA008
- 999 __
- $a ok $b bmc $g 1195197 $s 971290
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 62 $c 2 $d 127-138 $e 20161027 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- LZP __
- $a Pubmed-20170321